STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,080 | -73.3% | 10,934 | -28.0% | 0.00% | – |
| Q2 2023 | $161,492 | +501.9% | 15,192 | +371.7% | 0.00% | – |
| Q1 2023 | $26,831 | -53.8% | 3,221 | -48.9% | 0.00% | – |
| Q4 2022 | $58,131 | -28.2% | 6,298 | 0.0% | 0.00% | – |
| Q3 2022 | $81,000 | +17.4% | 6,298 | +20.1% | 0.00% | – |
| Q2 2022 | $69,000 | -37.8% | 5,242 | -0.7% | 0.00% | – |
| Q1 2022 | $111,000 | -12.6% | 5,281 | 0.0% | 0.00% | – |
| Q4 2021 | $127,000 | -5.2% | 5,281 | +0.6% | 0.00% | – |
| Q3 2021 | $134,000 | +45.7% | 5,252 | +93.1% | 0.00% | – |
| Q2 2021 | $92,000 | +17.9% | 2,720 | +35.7% | 0.00% | – |
| Q1 2021 | $78,000 | -29.1% | 2,005 | +12.3% | 0.00% | – |
| Q4 2020 | $110,000 | +39.2% | 1,785 | -23.7% | 0.00% | – |
| Q3 2020 | $79,000 | +61.2% | 2,340 | +13.6% | 0.00% | – |
| Q2 2020 | $49,000 | -18.3% | 2,059 | -21.4% | 0.00% | – |
| Q1 2020 | $60,000 | +17.6% | 2,618 | +45.3% | 0.00% | – |
| Q4 2019 | $51,000 | +59.4% | 1,802 | +20.9% | 0.00% | – |
| Q3 2019 | $32,000 | – | 1,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |